Caribou Biosciences, Inc. (CRBU)
After hours:
| Previous close | 2.4400 |
| Open | 2.5000 |
| Bid | 2.4700 x 1300 |
| Ask | 2.5000 x 1300 |
| Day's range | 2.4500 - 2.5700 |
| 52-week range | 1.5000 - 8.3300 |
| Volume | |
| Avg. volume | 2,608,679 |
| Market cap | 224.891M |
| Beta (5Y monthly) | 2.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.25 |
Simply Wall St.Is Caribou Biosciences (NASDAQ:CRBU) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
GlobeNewswireCaribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to aut
GlobeNewswireCaribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation o
